Abstract
Cardiovascular disease is a frequent complication and the most common cause of death in patients with CKD. Despite landmark medical advancements, mortality due to cardiovascular disease is still 20 times higher in CKD patients than in the general population, which is mainly due to the high prevalence of risk factors in this group. Indeed, in addition to traditional cardiovascular risk factors, CKD patients are exposed to nontraditional ones, which include metabolic, hormonal, and inflammatory alterations. The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has brought novel challenges for both cardiologists and nephrologists alike. Emerging evidence indicates that coronavirus disease 2019 (COVID-19) increases the risk of cardiovascular events and that several aspects of the disease may synergize with pre-existing cardiovascular risk factors in CKD patients. A better understanding of these mechanisms is pivotal for the prevention and treatment of cardiovascular events in this context, and we believe that additional clinical and experimental studies are needed to improve cardiovascular outcomes in CKD patients with COVID-19. In this review, we provide a summary of traditional and nontraditional cardiovascular risk factors in CKD patients, discussing their interaction with SARS-CoV-2 infection and focusing on CO-VID-19-related cardiovascular complications that may severely affect short- and long-term outcomes in this high-risk population.
References
1.
Saran
R
, Robinson
B
, Abbott
KC
, Agodoa
LYC
, Bragg-Gresham
J
, Balkrishnan
R
, US renal data system 2018 annual data report: epidemiology of kidney disease in the United States
. Am J Kidney Dis
. 2019 Mar
;73
(3 Suppl 1
):A7
–8
. .2.
Kliger
AS
, Cozzolino
M
, Jha
V
, Harbert
G
, Ikizler
TA
. Managing the COVID-19 pandemic: international comparisons in dialysis patients
. Kidney Int
. 2020 Jul
;98
(1
):12
–6
. .3.
Cozzolino
M
, Piccoli
GB
, Ikizler
TA
, Ronco
C
. The COVID-19 infection in dialysis: are home-based renal replacement therapies a way to improve patient management?
J Nephrol
. 2020
;33
(4
):629
–31
. .4.
Shi
S
, Qin
M
, Shen
B
, Cai
Y
, Liu
T
, Yang
F
, Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
. JAMA Cardiol
. 2020 Jul 1
;5
(7
):802
–10
. .5.
Giustino
G
, Pinney
SP
, Lala
A
, Reddy
VY
, Johnston-Cox
HA
, Mechanick
JI
, Coronavirus and cardiovascular disease, myocardial injury, and arrhythmia: JACC focus seminar
. J Am Coll Cardiol
. 2020 Oct
;76
(17
):2011
–23
. .6.
Huang
C
, Wang
Y
, Li
X
, Ren
L
, Zhao
J
, Hu
Y
, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
. Lancet
. 2020 Feb
;395
(10223
):497
–506
. .7.
Guan
W
, Ni
Z
, Hu
Y
, Liang
W
, Ou
C
, He
J
, Clinical characteristics of coronavirus disease 2019 in China
. N Engl J Med
. 2020 Apr
;382
(18
):1708
–20
. .8.
Gansevoort
RT
, Hilbrands
LB
. CKD is a key risk factor for COVID-19 mortality
. Nat Rev Nephrol
. 2020 Dec
;16
(12
):705
–6
.9.
Docherty
AB
, Harrison
EM
, Green
CA
, Hardwick
HE
, Pius
R
, Norman
L
, Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: prospective observational cohort study
. BMJ
. 2020 May
;369
:m1985
. .10.
Cheng
Y
, Luo
R
, Wang
K
, Zhang
M
, Wang
Z
, Dong
L
, Kidney disease is associated with in-hospital death of patients with COVID-19
. Kidney Int
. 2020
;97
(5
):829
–38
. .11.
Chan
L
, Chaudhary
K
, Saha
A
, Chauhan
K
, Vaid
A
, Zhao
S
, AKI in hospitalized patients with COVID-19
. J Am Soc Nephrol
. 2020 Jan
;32
(1
):151
–60
.12.
Hajar
R
. Framingham contribution to cardiovascular disease
. Heart Views
. 2016
;17
(2
):78
–81
. .13.
Vlagopoulos
PT
, Sarnak
MJ
. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease
. Med Clin North Am
. 2005 May
;89
(3
):587
–611
. .14.
Weiner
DE
, Tighiouart
H
, Elsayed
EF
, Griffith
JL
, Salem
DN
, Levey
AS
, The Framingham predictive instrument in chronic kidney disease
. J Am Coll Cardiol
. 2007 Jul
;50
(3
):217
–24
. .15.
Iseki
K
, Iseki
C
, Ikemiya
Y
, Fukiyama
K
. Risk of developing end-stage renal disease in a cohort of mass screening
. Kidney Int
. 1996 Mar
;49
(3
):800
–5
. .16.
Afkarian
M
, Sachs
MC
, Kestenbaum
B
, Hirsch
IB
, Tuttle
KR
, Himmelfarb
J
, Kidney disease and increased mortality risk in type 2 diabetes
. J Am Soc Nephrol
. 2013 Feb
;24
(2
):302
–8
. .17.
Afkarian
M
, Katz
R
, Bansal
N
, Correa
A
, Kestenbaum
B
, Himmelfarb
J
, Diabetes, kidney disease and cardiovascular outcomes in the Jackson Heart Study
. JAMA Cardiol
. 2017 Mar
;2
(3
):314
–8
.18.
Cheung
AK
, Sarnak
MJ
, Yan
G
, Dwyer
JT
, Heyka
RJ
, Rocco
MV
, Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients
. Kidney Int
. 2000 Jul
;58
(1
):353
–62
. .19.
Harnett
JD
, Foley
RN
, Kent
GM
, Barre
PE
, Murray
D
, Parfrey
PS
. Congestive heart failure in dialysis patients: prevalence, incidence, prognosis and risk factors
. Kidney Int
. 1995 Mar
;47
(3
):884
–90
. .20.
Hallan
SI
, Orth
SR
. Smoking is a risk factor in the progression to kidney failure
. Kidney Int
. 2011 Sep
;80
(5
):516
–23
. .21.
Jungers
P
, Massy
ZA
, Nguyen Khoa
T
, Fumeron
C
, Labrunie
M
, Lacour
B
, Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study
. Nephrol Dial Transplant
. 1997 Dec
;12
(12
):2597
–602
. .22.
Longenecker
JC
, Coresh
J
, Powe
NR
, Levey
AS
, Fink
NE
, Martin
A
, Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study
. J Am Soc Nephrol
. 2002 Jul
;13
(7
):1918
–27
. .23.
Lazarus
JM
, Bourgoignie
JJ
, Buckalew
VM
, Greene
T
, Levey
AS
, Milas
NC
, Achievement and safety of a low blood pressure goal in chronic renal disease
. Hypertension
. 1997 Feb
;29
(2
):641
–50
.24.
Sarafidis
P
, Loutradis
C
, Ortiz
A
, Ruilope
LM
. Blood pressure targets in patients with chronic kidney disease: MDRD and AASK now confirming SPRINT
. Clin Kidney J
. 2020 Jun
;13
(3
):287
–90
. .25.
Zager
PG
, Nikolic
J
, Brown
RH
, Campbell
MA
, Hunt
WC
, Peterson
D
, “U” curve association of blood pressure and mortality in hemodialysis patients. Medical Directors of Dialysis Clinic, Inc
. Kidney Int
. 1998 Aug
;54
(2
):561
–9
. .26.
Levin
A
, Singer
J
, Thompson
CR
, Ross
H
, Lewis
M
. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention
. Am J Kidney Dis
. 1996 Mar
;27
(3
):347
–54
. .27.
Di Lullo
L
, Gorini
A
, Russo
D
, Santoboni
A
, Ronco
C
. Left ventricular hypertrophy in chronic kidney disease patients: from pathophysiology to treatment
. Cardiorenal Med
. 2015 Oct
;5
(4
):254
–66
. .28.
Mikolasevic
I
, Žutelija
M
, Mavrinac
V
, Orlic
L
. Dyslipidemia in patients with chronic kidney disease: etiology and management
. Int J Nephrol Renovasc Dis
. 2017 Feb
;10
:35
–45
. .29.
Tonelli
M
, Muntner
P
, Lloyd
A
, Manns
B
, Klarenbach
S
, Pannu
N
, Association between LDL-C and risk of myocardial infarction in CKD
. J Am Soc Nephrol
. 2013 May
;24
(6
):979
–86
. .30.
Wanner
C
, Krane
V
, März
W
, Olschewski
M
, Mann
JF
, Ruf
G
, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
. N Engl J Med
. 2005 Jul
;353
(3
):238
–48
. .31.
Fellström
BC
, Jardine
AG
, Schmieder
RE
, Holdaas
H
, Bannister
K
, Beutler
J
, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis
. N Engl J Med
. 2009 Apr
;360
(14
):1395
–407
. .32.
Kovesdy
CP
, Furth
SL
, Zoccali
C
. Obesity and kidney disease: hidden consequences of the epidemic
. Kidney Dis
. 2017 Mar
;3
(1
):33
. .33.
Ladhani
M
, Craig
JC
, Irving
M
, Clayton
PA
, Wong
G
. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis
. Nephrol Dial Transplant
. 2017 Mar 1
;32
(3
):439
–49
. .34.
Manjunath
G
, Tighiouart
H
, Ibrahim
H
, MacLeod
B
, Salem
DN
, Griffith
JL
, Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community
. J Am Coll Cardiol
. 2003 Jan
;41
(1
):47
–55
. .35.
Go
AS
, Chertow
GM
, Fan
D
, McCulloch
CE
, Hsu
CY
. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
. N Engl J Med
. 2004 Sep 23
;351
(13
):1296
–305
. .36.
Gerstein
HC
, Mann
JF
, Yi
Q
, Zinman
B
, Dinneen
SF
, Hoogwerf
B
, Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals
. JAMA
. 2001 Jul
;286
(4
):421
–6
. .37.
Wachtell
K
, Ibsen
H
, Olsen
MH
, Borch-Johnsen
K
, Lindholm
LH
, Mogensen
CE
, Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study
. Ann Intern Med
. 2003 Dec
;139
(11
):901
–6
. .38.
Cozzolino
M
, Mangano
M
, Stucchi
A
, Ciceri
P
, Conte
F
, Galassi
A
. Cardiovascular disease in dialysis patients
. Nephrol Dial Transplant
. 2018 01
;33
(Suppl 3
):iii28
–34
. .39.
Grassi
G
, Quarti-Trevano
F
, Seravalle
G
, Arenare
F
, Volpe
M
, Furiani
S
, Early sympathetic activation in the initial clinical stages of chronic renal failure
. Hypertension
. 2011 Apr
;57
(4
):846
–51
. .40.
Converse
RL
, Jacobsen
TN
, Toto
RD
, Jost
CM
, Cosentino
F
, Fouad-Tarazi
F
, Sympathetic overactivity in patients with chronic renal failure
. N Engl J Med
. 1992 Dec
;327
(27
):1912
–8
. .41.
Kendrick
J
, Chonchol
MB
. Nontraditional risk factors for cardiovascular disease in patients with chronic kidney disease
. Nat Clin Pract Nephrol
. 2008 Dec
;4
(12
):672
–81
. .42.
Hung
SC
, Kuo
KL
, Peng
CH
, Wu
CH
, Lien
YC
, Wang
YC
, Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease
. Kidney Int
. 2014 Mar
;85
(3
):703
–9
. .43.
Kalantar-Zadeh
K
, Regidor
DL
, Kovesdy
CP
, Van Wyck
D
, Bunnapradist
S
, Horwich
TB
, Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis
. Circulation
. 2009 Feb
;119
(5
):671
–9
. .44.
Oberg
BP
, McMenamin
E
, Lucas
FL
, McMonagle
E
, Morrow
J
, Ikizler
TA
, Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease
. Kidney Int
. 2004 Mar
;65
(3
):1009
–16
. .45.
Kooman
JP
, Kotanko
P
, Schols
AM
, Shiels
PG
, Stenvinkel
P
. Chronic kidney disease and premature ageing
. Nat Rev Nephrol
. 2014 Dec
;10
(12
):732
–42
. .46.
Jankowska
M
, Cobo
G
, Lindholm
B
, Stenvinkel
P
. Inflammation and protein-energy wasting in the uremic milieu
. Contrib Nephrol
. 2017
;191
:58
–71
. .47.
Ioannou
K
, Stel
VS
, Dounousi
E
, Jager
KJ
, Papagianni
A
, Pappas
K
, Inflammation, endothelial dysfunction and increased left ventricular mass in chronic kidney disease (CKD) patients: a Longitudinal Study
. PLoS One
. 2015 Sep
;10
(9
):e0138461
. .48.
Arici
M
, Walls
J
. End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link?
Kidney Int
. 2001 Feb
;59
(2
):407
–14
. .49.
Weiner
DE
, Tighiouart
H
, Elsayed
EF
, Griffith
JL
, Salem
DN
, Levey
AS
, The relationship between nontraditional risk factors and outcomes in individuals with stage 3 to 4 CKD
. Am J Kidney Dis
. 2008 Feb
;51
(2
):212
–23
. .50.
Menon
V
, Greene
T
, Wang
X
, Pereira
AA
, Marcovina
SM
, Beck
GJ
, C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
. Kidney Int
. 2005 Aug
;68
(2
):766
–72
. .51.
Yeun
JY
, Levine
RA
, Mantadilok
V
, Kaysen
GA
. C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients
. Am J Kidney Dis
. 2000 Mar
;35
(3
):469
–76
. .52.
Dounousi
E
, Papavasiliou
E
, Makedou
A
, Ioannou
K
, Katopodis
KP
, Tselepis
A
, Oxidative stress is progressively enhanced with advancing stages of CKD
. Am J Kidney Dis
. 2006 Nov
;48
(5
):752
–60
. .53.
Nakagami
H
, Takemoto
M
, Liao
JK
. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy
. J Mol Cell Cardiol
. 2003 Jul
;35
(7
):851
–9
. .54.
Tumur
Z
, Niwa
T
. Indoxyl sulfate inhibits nitric oxide production and cell viability by inducing oxidative stress in vascular endothelial cells
. Am J Nephrol
. 2009
;29
(6
):551
–7
. .55.
Perticone
F
, Sciacqua
A
, Maio
R
, Perticone
M
, Maas
R
, Boger
RH
, Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension
. J Am Coll Cardiol
. 2005 Aug
;46
(3
):518
–23
. .56.
Cachofeiro
V
, Goicochea
M
, de Vinuesa
SG
, Oubiña
P
, Lahera
V
, Luño
J
. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease
. Kidney Int Suppl
. 2008 Dec
(111
):S4
–9
. .57.
Daenen
K
, Andries
A
, Mekahli
D
, Van Schepdael
A
, Jouret
F
, Bammens
B
. Oxidative stress in chronic kidney disease
. Pediatr Nephrol
. 2019
;34
(6
):975
–91
. .58.
McGovern
AP
, de Lusignan
S
, van Vlymen
J
, Liyanage
H
, Tomson
CR
, Gallagher
H
, Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study
. PLoS One
. 2013
;8
(9
):e74996
. .59.
Vervloet
MG
, Sezer
S
, Massy
ZA
, Johansson
L
, Cozzolino
M
, Fouque
D
, The role of phosphate in kidney disease
. Nat Rev Nephrol
. 2017 Jan
;13
(1
):27
–38
. .60.
Cozzolino
M
, Ciceri
P
, Galassi
A
, Mangano
M
, Carugo
S
, Capelli
I
, The key role of phosphate on vascular calcification
. Toxins
. 2019 Apr 9
;11
(4
):213
. .61.
Chen
J
, Budoff
MJ
, Reilly
MP
, Yang
W
, Rosas
SE
, Rahman
M
, Coronary artery calcification and risk of cardiovascular disease and death among patients with chronic kidney disease
. JAMA Cardiol
. 2017 Jun 1
;2
(6
):635
–43
. .62.
Marwick
TH
, Amann
K
, Bangalore
S
, Cavalcante
JL
, Charytan
DM
, Craig
JC
, Chronic kidney disease and valvular heart disease: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference
. Kidney Int
. 2019 Oct
;96
(4
):836
–49
. .63.
Galassi
A
, Cupisti
A
, Santoro
A
, Cozzolino
M
. Phosphate balance in ESRD: diet, dialysis and binders against the low evident masked pool
. J Nephrol
. 2015 Aug
;28
(4
):415
–29
. .64.
Hu
MC
, Kuro-o
M
, Moe
OW
. The emerging role of Klotho in clinical nephrology
. Nephrol Dial Transplant
. 2012 Jul
;27
(7
):2650
–7
. .65.
Faul
C
, Amaral
AP
, Oskouei
B
, Hu
MC
, Sloan
A
, Isakova
T
, FGF23 induces left ventricular hypertrophy
. J Clin Invest
. 2011 Nov
;121
(11
):4393
–408
. .66.
Gutiérrez
OM
, Mannstadt
M
, Isakova
T
, Rauh-Hain
JA
, Tamez
H
, Shah
A
, Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis
. N Engl J Med
. 2008 Aug
;359
(6
):584
–92
. .67.
Isakova
T
, Xie
H
, Yang
W
, Xie
D
, Anderson
AH
, Scialla
J
, Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease
. JAMA
. 2011 Jun
;305
(23
):2432
–9
. .68.
Weiskopf
RB
, Viele
MK
, Feiner
J
, Kelley
S
, Lieberman
J
, Noorani
M
, Human cardiovascular and metabolic response to acute, severe isovolemic anemia
. JAMA
. 1998 Jan
;279
(3
):217
–21
. .69.
Anand
IS
. Pathophysiology of anemia in heart failure
. Heart Fail Clin
. 2010 Jul
;6
(3
):279
–88
. .70.
Levin
A
, Thompson
CR
, Ethier
J
, Carlisle
EJ
, Tobe
S
, Mendelssohn
D
, Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin
. Am J Kidney Dis
. 1999 Jul
;34
(1
):125
–34
. .71.
Weiner
DE
, Tighiouart
H
, Vlagopoulos
PT
, Griffith
JL
, Salem
DN
, Levey
AS
, Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease
. J Am Soc Nephrol
. 2005 Jun
;16
(6
):1803
–10
. .72.
Nishiga
M
, Wang
DW
, Han
Y
, Lewis
DB
, Wu
JC
. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives
. Nat Rev Cardiol
. 2020 Sep
;17
(9
):543
–58
. .73.
Driggin
E
, Madhavan
MV
, Bikdeli
B
, Chuich
T
, Laracy
J
, Biondi-Zoccai
G
, Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic
. J Am Coll Cardiol
. 2020 May 12
;75
(18
):2352
–71
. .74.
Topol
EJ
. COVID-19 can affect the heart
. Science
. 2020 Oct
;370
(6515
):408
–9
. .75.
Zores
F
, Rebeaud
ME
. COVID and the renin-angiotensin system: are hypertension or its treatments deleterious?
Front Cardiovasc Med
. 2020
;7
:71
. .76.
Kuba
K
, Imai
Y
, Rao
S
, Gao
H
, Guo
F
, Guan
B
, A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury
. Nat Med
. 2005 Aug
;11
(8
):875
–9
.77.
Oudit
GY
, Kassiri
Z
, Jiang
C
, Liu
PP
, Poutanen
SM
, Penninger
JM
, SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS
. Eur J Clin Invest
. 2009 Jul
;39
(7
):618
–25
. .78.
Ronco
C
, Reis
T
, Cozzolino
M
. Rationale for medium cutoff membranes in COVID-19 patients requiring renal replacement therapy
. Nephron
. 2020
;144
(11
):550
–4
. .79.
Ronco
C
, Reis
T
. Kidney involvement in COVID-19 and rationale for extracorporeal therapies
. Nat Rev Nephrol
. 2020 Jun
;16
(6
):308
–10
.80.
Villa
G
, Romagnoli
S
, De Rosa
S
, Greco
M
, Resta
M
, Pomarè Montin
D
, Blood purification therapy with a hemodiafilter featuring enhanced adsorptive properties for cytokine removal in patients presenting COVID-19: a pilot study
. Crit Care
. 2020 Oct
;24
(1
):605
. .81.
Nalesso
F
, Garzotto
F
, Cattarin
L
, Gobbi
L
, Qassim
L
, Sgarabotto
L
, A continuous renal replacement therapy protocol for patients with acute kidney injury in intensive care unit with COVID-19
. J Clin Med
. 2020 May 19
;9
(5
):1529
. .82.
Asgharpour
M
, Mehdinezhad
H
, Bayani
M
, Zavareh
MSH
, Hamidi
SH
, Akbari
R
, Effectiveness of extracorporeal blood purification (hemoadsorption) in patients with severe coronavirus disease 2019 (COVID-19)
. BMC Nephrol
. 2020 Aug
;21
(1
):356
. .83.
Zhou
F
, Yu
T
, Du
R
, Fan
G
, Liu
Y
, Liu
Z
, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
. Lancet
. 2020 Mar
;395
(10229
):1054
–62
. .84.
Guo
T
, Fan
Y
, Chen
M
, Wu
X
, Zhang
L
, He
T
, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)
. JAMA Cardiol
. 2020 Jul 1
;5
(7
):811
–8
. .85.
Inciardi
RM
, Lupi
L
, Zaccone
G
, Italia
L
, Raffo
M
, Tomasoni
D
, Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)
. JAMA Cardiol
. 2020 Jul 1
;5
(7
):819
–24
. .86.
Wang
S
, Wei
X
, Hu
H
. STAR evidence evaluation of viral fulminant myocarditis: specificity, timeliness, accessibility, risk
. Eur Heart J
. 2020 Sep
;41
(34
):3281
–2
. .87.
Libby
P
, Loscalzo
J
, Ridker
PM
, Farkouh
ME
, Hsue
PY
, Fuster
V
, Inflammation, immunity, and infection in atherothrombosis: JACC review topic of the week
. J Am Coll Cardiol
. 2018 Oct 23
;72
(17
):2071
–81
. .88.
Solomon
MD
, McNulty
EJ
, Rana
JS
, Leong
TK
, Lee
C
, Sung
SH
, The Covid-19 pandemic and the incidence of acute myocardial infarction
. N Engl J Med
. 2020 Aug
;383
(7
):691
–3
. .89.
Mafham
MM
, Spata
E
, Goldacre
R
, Gair
D
, Curnow
P
, Bray
M
, COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England
. Lancet
. 2020 Aug
;396
(10248
):381
–9
. .90.
De Rosa
S
, Spaccarotella
C
, Basso
C
, Calabrò
MP
, Curcio
A
, Filardi
PP
, Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era
. Eur Heart J
. 2020 Jun 7
;41
(22
):2083
–8
. .91.
Masoudi
FA
, Plomondon
ME
, Magid
DJ
, Sales
A
, Rumsfeld
JS
. Renal insufficiency and mortality from acute coronary syndromes
. Am Heart J
. 2004 Apr
;147
(4
):623
–9
. .92.
Chertow
GM
, Normand
SL
, McNeil
BJ
. “Renalism”: inappropriately low rates of coronary angiography in elderly individuals with renal insufficiency
. J Am Soc Nephrol
. 2004 Sep
;15
(9
):2462
–8
. .93.
Wang
D
, Hu
B
, Hu
C
, Zhu
F
, Liu
X
, Zhang
J
, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China
. JAMA
. 2020 Mar 17
;323
(11
):1061
–9
. .94.
Wen
W
, Zhang
H
, Zhou
M
, Cheng
Y
, Ye
L
, Chen
J
, Arrhythmia in patients with severe coronavirus disease (COVID-19): a meta-analysis
. Eur Rev Med Pharmacol Sci
. 2020
;24
(21
):11395
–401
. .95.
Bhatla
A
, Mayer
MM
, Adusumalli
S
, Hyman
MC
, Oh
E
, Tierney
A
, COVID-19 and cardiac arrhythmias
. Heart Rhythm
. 2020 Sep
;17
(9
):1439
–44
. .96.
Peltzer
B
, Manocha
KK
, Ying
X
, Kirzner
J
, Ip
JE
, Thomas
G
, Outcomes and mortality associated with atrial arrhythmias among patients hospitalized with COVID-19
. J Cardiovasc Electrophysiol
. 2020 Oct
.97.
Liu
P
, Wang
L
, Han
D
, Sun
C
, Xue
X
, Li
G
. Acquired long QT syndrome in chronic kidney disease patients
. Ren Fail
. 2019 Dec
;42
(1
):54
–65
. .98.
Turagam
MK
, Musikantow
D
, Goldman
ME
, Bassily-Marcus
A
, Chu
E
, Shivamurthy
P
, Malignant arrhythmias in patients with COVID-19: incidence, mechanisms, and outcomes
. Circ Arrhythm Electrophysiol
. 2020
;13
(11
):e008920
. .99.
Cavalcanti
AB
, Zampieri
FG
, Rosa
RG
, Azevedo
LCP
, Veiga
VC
, Avezum
A
, Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
. N Engl J Med
. 2020 Nov
;383
(21
):2041
–52
. .100.
Furtado
RHM
, Berwanger
O
, Fonseca
HA
, Corrêa
TD
, Ferraz
LR
, Lapa
MG
, Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
. Lancet
. 2020 Oct
;396
(10256
):959
–67
. .101.
WHO Solidarity Trial Consortium
; Pan
H
, Peto
R
, Karim
QA
, Alejandria
M
, Henao-Restrepo
AM
, Repurposed antiviral drugs for COVID-19: interim WHO solidarity trial results
. medRxiv
. 2020 Oct
. .102.
Chen
T
, Wu
D
, Chen
H
, Yan
W
, Yang
D
, Chen
G
, Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
. BMJ
. 2020 Mar
;368
:m1091
. .103.
Ruan
Q
, Yang
K
, Wang
W
, Jiang
L
, Song
J
. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China
. Intensive Care Med
. 2020 May
;46
(5
):846
–8
. .104.
Tagore
R
, Ling
LH
, Yang
H
, Daw
HY
, Chan
YH
, Sethi
SK
. Natriuretic peptides in chronic kidney disease
. Clin J Am Soc Nephrol
. 2008 Nov
;3
(6
):1644
–51
. .105.
Heywood
JT
, Fonarow
GC
, Costanzo
MR
, Mathur
VS
, Wigneswaran
JR
, Wynne
J
, High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database
. J Card Fail
. 2007 Aug
;13
(6
):422
–30
. .106.
Vaduganathan
M
, Vardeny
O
, Michel
T
, McMurray
JJV
, Pfeffer
MA
, Solomon
SD
. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
. N Engl J Med
. 2020 Apr
;382
(17
):1653
–9
. .107.
Cohen
JB
, Hanff
TC
, William
P
, Sweitzer
N
, Rosado-Santander
NR
, Medina
C
, Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
. Lancet Respir Med
. 2021 Jan
. .108.
Al-Samkari
H
, Karp Leaf
RS
, Dzik
WH
, Carlson
JCT
, Fogerty
AE
, Waheed
A
, COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection
. Blood
. 2020 Jul
;136
(4
):489
–500
. .109.
Klok
FA
, Kruip
MJHA
, van der Meer
NJM
, Arbous
MS
, Gommers
DAMPJ
, Kant
KM
, Incidence of thrombotic complications in critically ill ICU patients with COVID-19
. Thromb Res
. 2020 Jul
;191
:145
–7
. .110.
Cui
S
, Chen
S
, Li
X
, Liu
S
, Wang
F
. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia
. J Thromb Haemost
. 2020
;18
(6
):1421
–4
. .111.
Oudkerk
M
, Büller
HR
, Kuijpers
D
, van Es
N
, Oudkerk
SF
, McLoud
T
, Diagnosis, prevention, and treatment of thromboembolic complications in COVID-19: report of the national institute for public health of the Netherlands
. Radiology
. 2020 Apr
;297
(1
):E216
–22
. .112.
Chowdhury
JF
, Moores
LK
, Connors
JM
. Anticoagulation in hospitalized patients with Covid-19
. N Engl J Med
. 2020 Oct
;383
(17
):1675
–8
. .113.
Aursulesei
V
, Costache
II
. Anticoagulation in chronic kidney disease: from guidelines to clinical practice
. Clin Cardiol
. 2019 May
;42
(8
):774
–82
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
